Hemangioendothelioma
Symptoms, Doctors, Treatments, Advances & More

Hemangioendothelioma Overview

Save information for later
Sign Up

Learn About Hemangioendothelioma

What is the definition of Hemangioendothelioma?
The term Hemangioendothelioma describes several types of vascular neosplasms and includes both non-cancerous (benign) and cancerous (malignant) growths. The term has also been applied to those that show "borderline" behavior, intermediate between entirely benign hemangiomas and highly malignant angiosarcomas. Hemangioendotheliomas are caused by abnormal growth of blood vessel cells, although the exact underlying cause for the abnormal growth is unknown. They can also develop in an organ, such as the liver or lung. They usually grow slowly and can sometimes spread to other tissues in the body (metastasize). Examples of types of Hemangioendotheliomas include spindle cell hemangioma; papillary intralymphatic (Dabska tumor); retiform; kaposiform; epithelioid; pseudomyogenic (epithelioid sarcoma-like Hemangioendothelioma); and composite.
What are the alternative names for Hemangioendothelioma?
  • Hemangioendothelioma
Who are the top Hemangioendothelioma Local Doctors?
Elite in Hemangioendothelioma
Silvia Stacchiotti
Elite in Hemangioendothelioma
Silvia Stacchiotti
Referral may be required
Milan, IT 

Silvia Stacchiotti practices practicing medicine in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Hemangioendothelioma, and Synovectomy.

Advanced in Hemangioendothelioma
Dr. Mandi J. Greenway
Dermatology
Advanced in Hemangioendothelioma
Dr. Mandi J. Greenway
Dermatology
Referral may be required

Avera Medical Group Dermatology — Mitchell

1900 Grassland Dr 3rd, Floor, 
Mitchell, SD 
605-995-7020
Languages Spoken:
English
See accepted insurances

Mandi Greenway, MD, a dermatologist, provides expert skin care for people of all ages at Avera Medical Group Dermatology in Mitchell, SD. Dr. Greenway is rated as an Advanced provider by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Warts, Seborrheic Keratosis, and Melanoma. Dr. Greenway is board certified in American Board Of Dermatology.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Hemangioendothelioma
Dr. Katie D. Bonnichsen
Dermatology
Advanced in Hemangioendothelioma
Dr. Katie D. Bonnichsen
Dermatology
Referral may be required

Avera Dermatology — Pierre

801 E Sioux Ave, Floor 2, 
Pierre, SD 
605-945-5217
Languages Spoken:
English
See accepted insurances

Dr. Katie Bonnichsen, a dermatologist, provides expert skin care at Avera Medical Group located in the Helmsley Center at Avera St. Mary's Hospital in Pierre, SD. Dr. Bonnichsen is rated as an Advanced provider by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Seborrheic Keratosis, Warts, and Kaposiform Hemangioendothelioma. Dr. Bonnichsen is board certified in Eligible - American Board Of Dermatology.

View All Doctors
What are the latest Hemangioendothelioma Clinical Trials?
Low-dose Versus High-dose Sirolimus Combined With Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: a Randomized Noninferiority Trial
Low-dose Versus High-dose Sirolimus Combined With Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: a Randomized Noninferiority Trial
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: This randomized clinical trial evaluates if low-dose sirolimus (target trough 4-8 ng/mL) combined with prednisolone is noninferior in efficacy but superior in safety compared to standard high-dose sirolimus (target trough 10-15 ng/mL) combined with prednisolone in pediatric patients with kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon (KHE with KMP), with participants randomized 1:...

Match to trials
Find the right clinical trials for you in under a minute
Get started
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Enrollment Status: Recruiting
Publish Date: May 26, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-s...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center